Background: Rituximab is a Second-line treatment for immune thrombocytopenia.Rituximab is expensive and patients in Yunnan have different understanding of the drug and affordability of the economy, and selection of rituximab requires a combination of patient characteristics, availability of the drug, and treatment experience at a single center.

Aims: This study performed a retrospective approach to analyze the use of rituximab in patients with ITP to summarize the treatment experience and provide a single center data analysis.

Methods: The clinical materials of patients who were admitted to the Department of Hematology the Second Affiliated Hospital of Kunming Medical University from January 2014 to July 2020 were collected.

Results: For group low-dose rituximab therapy：The median age was 45 (23~66) years,median disease duration was 13.5 (1~136) months, median follow-up time was 27(6~79) months.In the 15 patients with OR(50%), the median efficacy maintenance time was 12(3~ 40) months, early response in 13 patients, initial response in 15 patients, and sustained response in 12 patients, the response time more than 1 month in 14 patients and the response time less than 1 month in 2 patients. The 1-year response rate for all adults treated with rituximab was 40.9% and the 2-year response rate was 18.7%. The correlation between bleeding score and age, course of disease and platelet count before treatment was not statistically different (r=-0.04, P=0.985; r=0.073, P=0.701; r=-2.51, P=0.181).There was no significant difference in gender, age and disease stage between group NR and group OR.

Conclusion(s): The results showed that rituximab is an effective second-line treatment in the treatment of adult ITP, with mild adverse reactions, and no index can be used as a predictor of the efficacy of rituximab.

« Back to ISTH 2022 Congress

ISTH Congress Abstracts - https://abstracts.isth.org/abstract/clinical-efficacy-of-rituximab-in-the-treatment-of-adult-immune-thrombocytopenia-a-single-center-data-analysis/